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MARIBAVIR IS BIOEQUIVALENT IN FED AND FASTED HEALTHY
SUBJECTS
Goldwater, R.1, Johnson, J.2, Schumacher, M.2, Villano, S.2 1PAREXEL
International, Baltimore, MD; 2ViroPharma Incorporated, Exton,
PA
Background: Maribavir (MBV) is an orally bioavailable antiviral
drug with a novel mechanism of action against human cytomegalo-
virus (CMV) and a favorable tolerability profile. MBV is rapidly
and well absorbed following oral administration with peak plasma
concentrations generally achieved between 1.0 and 3.0 h post dose.
In single-dose studies in healthy (50–1600 mg) and HIV-infected
(100–1600 mg) subjects, the pharmacokinetics (PK) of MBV are
approximately linear. This study was designed to determine the
effect of co-administration of a moderately high-fat meal on the
pharmacokinetics of MBV.
Methods: This study was an open-label, randomized, crossover
design performed at one investigational site. The study population
included 15 men and 15 women and had a mean age of 29 years
(range, 21–40 years). Eighteen subjects (60%) were black and 12
(40%) were white. Subjects received a single 400-mg dose of MBV
administered as 2  200-mg tablets either after an overnight fast
or within 5 minutes after completion of a standard, moderately
high-fat breakfast. Treatments were separated by a 7- to 14-day
washout interval. A full pharmacokinetic (PK) evaluation was per-
formed over the 24 hours following each treatment. Standard safety
monitoring was performed.
Results: Oral MBV 400 mg was generally well tolerated when
administered under either fasting or fed conditions. The most
frequently reported treatment-emergent event was taste disturbance
which occurred in 14/29 (48%) subjects. Mean (SD) PK parameters
for MBV under fasting and fed conditions are shown below with
results from ANOVA.
Ratio ofFasting
With
FoodGeometric
Means (90%CI)Tmax (h) 1.57 (0.68) 2.47 (0.87) Different*
Cmax (mcg/mL) 16.7 (5.4) 11.7 (2.4) 0.722 (0.656, 0.793)
AUC(0-t) (mcg*h/mL) 101 (36.4) 86.3 (29.1) 0.860 (0.802, 0.922)
AUC(0-inf) (mcg*h/mL) 106 (42.0) 91.5 (33.9) 0.864 (0.804, 0.929)*For Tmax, the p-value for testing for treatment effects was\0.0001 for
MBV administered with food versus fasting conditions.
Time toMBVCmax was delayed by administration after a high fat
meal (Tmax 2.5 hours vs. 1.6 hours under fasting conditions). Al-
though there is a decrease in AUC when MBV is administered
with food, AUC values are considered equivalent as the 90% CIs
are within the 0.80 to 1.25 range. Based on the ratio of geometric
means of the two treatments, Cmax is 28% lower for MBV adminis-
tered with food compared with fasting conditions (p\0.0001).
Conclusions: A moderately high-fat meal was shown to have
a modest effect on Cmax of MBV and to delay Tmax by about 1
hour but does not substantially alter the total exposure toMBV.These
findings suggest that MBV can be taken without regard to food.295
SAFETY PROFILE OF PHARMACOKINETICALLY TARGETED INTRAVENOUS
BUSULFAN COMBINED WITH FLUDARABINE (BUFLU) AS CONDITIONING
PRIOR TO ALLOGENEIC PERIPHERAL BLOOD HEMATOPOIETIC CELL
TRANSPLANT
Perkins, J.1, Alsina,M.1, Ayala, E.1, Fancher, K.2, Fernandez, H.1, Khar-
fan-Dabaja, M.1, Ochoa-Bayona, L.1, Perez, L.1, Raychaudhuri, J.1,
Sullivan, D.1, Tate, C.2, Field, T.1 1Moffitt Cancer Center, Tampa,
FL; 2Moffitt Cancer Center, Tampa, FL
We report here our experience with 105 pts with hematologic ma-
lignancies treated with busulfan (Bu) and fludarabine (Flu) as condi-
tioning prior to allogeneic hematopoietic cell transplant. Bu was
dosed at 100–145mg/m2/day on days 1 and 2 with pharmacokinetic
targeting for days 3 and 4; the dose of Flu was 40mg/m2/day for 4days. The median age was 47.6 years (range 22–67 years). Forty-one
pts received grafts from matched siblings, 48 from matched URD,
and 16 from URD mismatched at 1 antigen/allele. Disease status
was categorized as low risk (no evidence of disease) in 54 pts, interme-
diate risk (\20% BM blasts or chemosensitive lymphoma) in 36 pts,
and high risk ($20%BMor any circulating blasts or chemorefractory
lymphoma) in 15 pts. Bu doses were targeted to area under the con-
centration time curve (AUC) value of 3500–5850 uM*min, depending
on diagnosis and disease status. Median actual AUC after a dose of
130mg/m2 was 4692 uM*min (range 2633–8219 uM*min) and doses
3 and 4 were adjusted in 69 pts (66%) to achieve the overall target
AUC. Median total Bu doses to achieve target AUC of 5300/day
was 520mg/m2 (range 332–1040mg/m2). Pts received tacrolimus
and methotrexate or mycophenolate as GVHD prophylaxis. Grade
2–4 and 3–4 acute GVHDoccurred in 76 (72%) and 24 (23%) pts, re-
spectively. Moderate to severe chronic GVHD occurred in 54 of 84
(64%) evaluable pts. All pts received anti-seizure prophylaxis with ei-
ther phenytoin or lorazepam; no seizures occurred within the first 72
hours after the completion of Bu. Moderate to severe toxicities ob-
served that were at least possibly related to Bu included grade 3 or
4 elevations in hepatic transaminases in 12 pts (11%), hepatic
VOD/SOS in 4 pts (4%), and interstitial pneumonitis in 2 pts (2%).
100 day and 1 year non-relapse mortality were 7% and 20% respec-
tively. Overall and event-free suvival at 2 years for the low risk versus
intermediate or high risk groups were 62% and 59% vs 39% and 33%
(p5 0.03 for both comparisons). We conclude that using pharmaco-
kinetically targeted busulfan in combination with fludarabine offers an
active and well-tolerated approach to allogeneic transplantation. Due
to the large range in dosing required to achieve a desired AUC, phar-
macokinetic targeting is recommended. While others are evaluating
the benefit of targeting Bu dosing in a more formal manner, we are
exploring the maximumally tolerated systemic exposure to Bu based
on pharmcokinetic targeting in a prospective clinical trial.296
PLATELET ENGRAFTMENT IN AML PATIENTS RECEIVING MATCHED RE-
LATED DONOR (MRD) ALLOGENEIC BONE MARROW TRANSPLANT (AL-
LOBMT) CORRELATES WITH MAJOR HISTOCOMPATIBILITY COMPLEX
CLASS I-RELATED MOLECULE A (MICA) GENE POLYMORPHISMS
Sobecks, R.M.1, Askar, M.2, Zhang, A.2, Thomas, D.2, Kawczak, P.2,
Pidwell, D.2, Rybicki, L.3, Jasek, M.1, Kalaycio, M.1, Andresen, S.1,
Pohlman, B.1, Dean, R.1, Copelan, E.1, Maciejewski, J.1, Bolwell, B.1
1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; 2Cleveland
Clinic, Cleveland, OH; 3Cleveland Clinic, Cleveland, OH
Recipient immune effector cells such as CD81, TCRab1 and
TCRgd1 T cells as well as NK cells have been implicated in resis-
tance to platelet engraftment (PE) after alloBMT. MICA is a ligand
recognized by the activating receptor NKG2D that is expressed on
the surface of NK, NKT, CD81 and TCRgd1 T cells. Allelic vari-
ants of MICA due to a single amino acid substitution at position 129
in the alpha2 domain have been reported to result in large differences
in NKG2D binding. MICA alleles with a methionine (129M) or va-
line (129V) have been classified as having strong or weak binding af-
finity for NKG2D, respectively. These variable affinities have been
suggested to affect thresholds of NK cell triggering and T cell mod-
ulation. It has also been reported that homozygosity of 129M alleles
was associated with early onset ankylosing spondylitis. However, the
effect such polymorphisms have on outcomes afterMRDalloBMT is
unknown. 69AMLptswho hadMRDalloBMTwith busulfan/cyclo-
phosphamide conditioning were genotyped to determineMICA 129
dimorphism. MICA typing was performed retrospectively on DNA
samples from donors and recipients by rSSOP. Pts were categorized
as 129VV (weak, n5 32), 129MV (mixed, n5 33) or 129MM(strong,
n 5 4) dimorphisms. Post-transplant outcomes were compared be-
tween pts with weak vs. mixed/strong binding affinities. Outcomes
were estimated using the Kaplan-Meier method and compared be-
tween groups with the log-rank test. Pts in the weak binding affinity
grouphadmore rapidPE to.20K/mLthan those in themixed/strong
group [median 17 vs. 25 days, respectively, p 5 0.006]. The weak
binding group also tended to have inferior relapse-free survival
(p 5 0.09). There were no differences between the weak and
mixed/strong binding affinity groups with regards to pre-BMT pt
characteristics, CD341/TNC doses, neutrophil engraftment, acute
